COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?
Catherine Bollard
• 26 Oct 2019
Catherine Bollard, MD, MBChB, Children’s National Medical Center, Washington, DC, discusses the possibility of third party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
